X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EXN407
Therapeutic Area: Ophthalmology Product Name: EXN407
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 02, 2021
Details:
In collaboration with Janssen Pharmaceuticals, the first patient has been dosed with Exonate's, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EXN407
Therapeutic Area: Ophthalmology Product Name: EXN407
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
First patient has been dosed with Exonate’s lead compound, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema (CI-DMO).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): hRPC stem cell
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
Details:
Company will present clinical and preclinical results in a number of diseases where mast cells and/or eosinophils have been shown to play a role in disease pathology.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
